English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, May 8, 2024
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
Monday, May 6, 2024
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
Tuesday, April 16, 2024
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Tuesday, April 2, 2024
Lexaria Awarded New Patents
Thursday, March 14, 2024
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Thursday, March 7, 2024
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Tuesday, March 5, 2024
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Monday, March 4, 2024
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study
Friday, March 1, 2024
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Saturday, February 17, 2024
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575